Susan B Glick1, David J Samson2, Elbert S Huang3, Vikrant Vats2, Naomi Aronson2, Stephen G Weber4. 1. Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: sglick@uchicago.edu. 2. Technology Evaluation Center, Evidence-Based Practice Center, Blue Cross Blue Shield Association, Chicago, IL. 3. Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, IL. 4. Section of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, Chicago, IL.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of health care-associated infections. Although the evidence in support of MRSA screening has been promising, a number of questions remain about the effectiveness of active surveillance. METHODS: We searched the literature for studies that examined MRSA acquisition, MRSA infection, morbidity, mortality, harms of screening, and resource utilization when screening for MRSA carriage was compared with no screening or with targeted screening. Because of heterogeneity of the data and weaknesses in study design, meta-analysis was not performed. Strength of evidence (SOE) was determined using the system developed by the Grading of Recommendations Assessment, Development and Evaluation Working Group. RESULTS: One randomized controlled trial and 47 quasi-experimental studies met our inclusion criteria. We focused on the 14 studies that addressed health care-associated outcomes and that attempted to control for confounding and/or secular trends, because those studies had the potential to support causal inferences. With universal screening for MRSA carriage compared with no screening, 2 large quasi-experimental studies found reductions in health care-associated MRSA infection. The SOE for this finding is low. For each of the other screening strategies evaluated, this review found insufficient evidence to determine the comparative effectiveness of screening. CONCLUSIONS: Although there is low SOE that universal screening of hospital patients decreases MRSA infection, there is insufficient evidence to determine the consequences of universal screening or the effectiveness of other screening strategies.
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of health care-associated infections. Although the evidence in support of MRSA screening has been promising, a number of questions remain about the effectiveness of active surveillance. METHODS: We searched the literature for studies that examined MRSA acquisition, MRSA infection, morbidity, mortality, harms of screening, and resource utilization when screening for MRSA carriage was compared with no screening or with targeted screening. Because of heterogeneity of the data and weaknesses in study design, meta-analysis was not performed. Strength of evidence (SOE) was determined using the system developed by the Grading of Recommendations Assessment, Development and Evaluation Working Group. RESULTS: One randomized controlled trial and 47 quasi-experimental studies met our inclusion criteria. We focused on the 14 studies that addressed health care-associated outcomes and that attempted to control for confounding and/or secular trends, because those studies had the potential to support causal inferences. With universal screening for MRSA carriage compared with no screening, 2 large quasi-experimental studies found reductions in health care-associated MRSA infection. The SOE for this finding is low. For each of the other screening strategies evaluated, this review found insufficient evidence to determine the comparative effectiveness of screening. CONCLUSIONS: Although there is low SOE that universal screening of hospital patientsdecreases MRSA infection, there is insufficient evidence to determine the consequences of universal screening or the effectiveness of other screening strategies.
Authors: Claire L Gorrie; Mirjana Mirceta; Ryan R Wick; David J Edwards; Nicholas R Thomson; Richard A Strugnell; Nigel F Pratt; Jill S Garlick; Kerri M Watson; David V Pilcher; Steve A McGloughlin; Denis W Spelman; Adam W J Jenney; Kathryn E Holt Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079
Authors: Virginia R Roth; Tara Longpre; Doug Coyle; Kathryn N Suh; Monica Taljaard; Katherine A Muldoon; Karamchand Ramotar; Alan Forster Journal: PLoS One Date: 2016-07-27 Impact factor: 3.240